Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ExpreS2ion’s CEO in interview on achievements in 2020 and the company’s outlook for 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with the company’s CEO Bent Frandsen, in which he sums up the company’s achievements in 2021 and the outlook for the rest of 2021 and beyond. This includes discussing the status of the ABNCoV2 COVID-19 vaccine program and the recently in-licensed ES2B-C001 HER2 breast cancer vaccine project.The CEO interview is available via this link: https://mailchi.mp/expres2ionbio.com/february2021   Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se

Coor acquires R & K Service in Norway

Coor today signed an agreement regarding the acquisition of Norwegian company R & K Service AS, which delivers cleaning and restaurant services. R & K Service has 130 employees with annual sales of some SEK 80 M. The acquisition strengthens Coor’s offering in cleaning and restaurant services and increases Coor’s geographical coverage in the Stavanger region.The purchase consideration (on a cash and debt free basis) amounts to some SEK 65 M and corresponds to an EV/EBITA multiple of approximately 7x in relation to current EBITA, and approximately 5x when expected synergies have been realized

RLS GLOBAL AB (publ) YEAR-END REPORT 2020

OCTOBER 1[st]–DECEMBER 31[st] · Net sales amounted to KSEK 139 (KSEK 54) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,2 (MSEK -8,9) · Earning per share before dilution at SEK -0,11 (SEK -0,15) · Cash flow from operating activities amounted to MSEK -7,0 (MSEK -5,7) · Liquid assets at the end of the period MSEK 18,9 (MSEK 41,7) · Equity ratio was 88 % (90 %)  JANUARY 1[st]–DECEMBER 31[st] · Net sales amounted to KSEK 2,043 (KSEK 1,023) · Earnings before interest and taxes (EBIT) amounted to MSEK -22,3 (MSEK -26,7) · Earning per share

Recipharm bolsters biologics offering

Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers’ vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms. The license, which applies to its facility in Wasserburg, Germany, also covers microbiological testing allowing Recipharm to insource bacterial endotoxin testing on its products, including testing diluent for one of the COVID-19 vaccines.  Kjell Johansson, President Manufacturing Services Europe

Axactor SE - Acceptances received under mandatory offer

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran").  On 9 February 2021,

Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the treatment of Ankylosing Spondylitis

Partners eye additional applications in autoimmune diseases during 2021  San Diego, U.S., Shanghai, China, and Solna, Sweden, February 10, 2021. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that the U.S. FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA). The partners are jointly developing izokibep to treat multiple autoimmune diseases, and Inmagene has taken the responsibility to manage the global clinical trials for axSpA.“Obtaining FDA IND

SimCorp A/S – New Share buyback program

Company Announcement no. 02/2021 SimCorp A/S (“SimCorp”) has today initiated a share buyback program for up to EUR 20.0m, to be executed during the period from 10 February 2021 to 31 July 2021. The buyback program is being launched in accordance with the authorization granted by the shareholders at the Annual General Meeting on 24 March 2020 to repurchase up to 10% of the SimCorp’s share capital in the period until the next annual general meeting. The buyback program will be structured and carried out in compliance with the provisions of Regulation No. 596/2014 of the European

Board of Directors’ Proposals to Raisio plc’s Annual General Meeting 2021

Raisio plc, Stock Exchange Release, 10 February 2021 Board of Directors’ Proposals to Raisio plc’s Annual General Meeting 2021 Raisio plc’s Annual General Meeting is planned to be held on 13 April 2021 at 2 p.m. (EET) in Raisio, Finland. The Annual General Meeting will be convened based on the temporary legislative act to limit the spread of Covid-19 pandemic (677/2020). Therefore, the shareholders and their proxy representatives will be able to participate in the Annual General Meeting and exercise the shareholders’ rights only by voting in advance and by submitting counterproposals

Rottneros announces price hike for SW BCTMP in South East Asia

Rottneros announces price hike of 75 USD/ton for all new SW BCTMP orders for South East Asian destinations effective from 10th of February 2021.The increase reflects that the overall pulp and SW BCTMP markets are in better balance today, following strong demand from the paper board and other paper segments as well as reduced inventories. Rottneros is a supplier of fibre for selected niche and speciality paper and board applications. Rottneros offers a wide selection of High Yield and Kraft Pulp (bleached and unbleached) made from sustainably managed Nordic soft wood forests.Kasper

INVITATION TO PRESENTATION OF Q4-2020 FINANCIAL RESULTS

Oslo, Norway (10 February 2021) — NattoPharma will release its fourth quarter financial results on Wednesday 17[th] February 2010 at approximately 07:00 CET. The report will be made available at www.nattopharma.com and at www.oslobors.no. The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results followed by an online Q&A session. Please follow the below link to join the web-cast, https://channel.royalcast.com/landingpage/hegnarmedia/20210217_9/ The presentation and following Q&A session will be conducted in English and it will be

Klarna launches bank account in Germany

Berlin, 10th of February 2021 - Klarna, the leading global payment and shopping service, is launching consumer bank accounts in Germany, with the aim to provide them with further control of their finances. The launch marks a first for the company and will allow customers to easily track, categorize and analyze all of their everyday spending using the Klarna app. A Klarna bank account will come with a Visa debit card which can also be connected to both Google Pay and Apple Pay. The offering will exclusively be made available to a limited number of Klarna’s most loyal consumers to intensively

Inhalation Sciences’ PreciseInhale receives extended international Registered Trademark

(Stockholm, 10 February 2021) PreciseInhale[®], Inhalation Sciences’ flagship high-precision aerosol generator for preclinical respiratory research, has received an extended international Registered Trademark from the International Bureau of the World Intellectual Property Organization (WIPO). ISAB CEO Manoush Masarrat: “This will play an important role in protection of our trademark and driving the growth of PreciseInhale[®] in many strategic global markets.”The new trademark will last for ten years and designates PreciseInhale[®] as unique and protected not only in the European market –

Q-Free: Traffic Management contract in the US – ~90 MNOK

Q-Free has signed a contract with a US customer to provide a new statewide advanced traffic management solution (ATMS). The delivery will include Q-Free’s OpenTMS software platform plus Traveler Information and Video Management solutions provided by partners.  Over the potential 10-year contract term, the total estimated contract value is close to 90 MNOK. The initial delivery accounts for approximately 20% of the value and will be delivered in September this year. Recurring Operations & Maintenance revenues account for the remaining 80%. There will also be opportunities for additional

Full Year Report January – December 2020

Strong finish to the year with top-line growth across all product segments · Record sales and operating profit for the year driven by strong traction for ZYN nicotine pouches in the US. Double-digit operating profit growth in local currencies for the Smokefree and Cigar product segments in both the full year and the fourth quarter. · COVID-19 related effects are estimated to have elevated sales and operating profit for the full year as well as in the fourth quarter. · In local currencies, sales increased by 15 percent for the fourth quarter and by 17 percent for the full year.

SOTKAMO SILVER AB: SOTKAMO SILVER AMENDS THE TERMS OF CONVERTIBLE 2019/2020

Press release: Stockholm, February 10, 2020 08:15 CETThe Board of Directors of Sotkamo Silver AB (”Sotkamo Silver” or the ”Company”) has in agreement with the convertible holder decided to amend the terms and conditions of the Company's outstanding convertibles 2019/2020 in the aggregate amount of SEK 15 million and the convertible holder has requested that conversion shall be made as soon as the new terms and conditions are registered with the Swedish Companies Registration Office. In May 2019, Sotkamo Silver issued convertibles in an aggregate nominal amount of SEK 15 million to Formue

Vestas Annual Report 2020 – Continued leadership in a challenging year

Vestas Wind Systems A/S, Aarhus, 10 February 2021Company announcement no. 01/2021   Vestas Annual Report 2020 – Continued leadership in a challenging year Summary: For the year 2020, Vestas’ revenue amounted to EUR 14.8bn, with an EBIT margin before special items of 5.1 percent, and total investments*[)] of EUR 659m, all in line with expectations. Compared to 2019, revenue increased while earnings decreased, and free cash flow*[)] stayed at around the same level. The value of the combined order backlog increased from EUR 34bn to 43bn as the offshore business is now included.

Adverty enters next phase of growth and global expansion by focusing founder Niklas Bakos on product strategy and promoting Tobias Knutsson to CEO

Adverty AB (publ) today announces the promotion of Tobias Knutsson to CEO, alongside the appointment of Thorbjörn Warin as Chief Supply Officer, with founder Niklas Bakos to focus on product strategy and development, as the leading in-game advertising specialist enters its next phase of growth and global expansion.Adverty, the leading in-game platform for advertisers, agencies and game developers, prepares for the next phase of growth in the commercialization of its seamless in-game brand advertising platform, by expanding the management team to accelerate developments within product and

Attendo's year-end report for 2020 – In a challenging quarter, development remained positive in Finland and was stable in Scandinavia. Attendo presents new financial targets for 2023.

Attendo reports continued organic growth and a stable result during the fourth quarter of 2020. The Finnish operations continue to show a positive development following the ongoing action programme and Scandinavia has seen a stable development despite a strong second wave of the pandemics. In conjunction with this report, Attendo presents new financial targets, including adjusted earnings per share of SEK 4 or better by 2023.President and CEO Martin Tivéus comments on the report “We continued to sell more beds in the fourth quarter and are reporting organic growth of five percent. The

ADDvise Group AB receives SEK 27.8 million through the warrants of series 2019/2021 – Regulatory information

Holders of warrants of series 2019/2021 subscribed for 42,787,137 warrants, corresponding to 99.41 percent of the outstanding warrants, for subscription of 42,787,137 shares of series B at the subscribtion price of SEK 0.65. Through the exercise of the warrants, ADDvise receives SEK 27,811,639 before issue costs. Background During the first quarter of 2019, ADDvise carried out a rights issue of units, consisting of one (1) newly issued series B share and one (1) warrant of series 2019/2021. Each warrant of series 2019/2021 entitled the holder to subscribe for one (1) new B share in

ABGSC – Q4 2020 Interim Report

Highlights: · Q4 was the strongest quarter in the firm’s history with revenues of NOK 893m (+77%) · Full year revenues of NOK 1,926m, up 43% (NOK 1,351m) · Full year Diluted EPS up 77% to NOK 0.78 (0.44) · Proposed final 2020 dividend of NOK 0.83 per share. Total combined 2020 cash distribution of NOK 1 per share CEO comment: 2020 was a year when we broke record after record, and the final quarter was no exception. Q4 turned out to be our best quarter ever. Although Q4 is normally our strongest, it well exceeded our expectations, as revenues reached NOK 893m (+77 % y-o-y)

Reminder: Invitation to presentation of Orkla’s fourth quarter 2020 results, Thursday 11 February

Orkla will report its fourth quarter 2020 results on Thursday, 11 February 2021 at 7.00 a.m. CET.The quarterly report and the presentation material will be available at this time at: https://investors.orkla.com.The results will be presented in a webcast with Presidet & CEO Jaan Ivar Semlitsch and CFO Harald Ullevoldsæter at 8.00 a.m. CET. As a consequence of the Corona situation, there will not be a physical presentation of the results.The presentation and subsequent Q&A session will be held in English and may be viewed live at https://investors.orkla.com (direct link: https://events.

Dividend amount in XACT Nordic High Dividend Low Volatility (UCITS ETF)

The dividend amount of the above stated Exchange Traded Fund is SEK 5.36 per fund unit.SEK 1.34 will be distributed in March, May, September and in November. Registered holder of fund units on the record day will receive dividend. The schedule for the dividend is as follows: Dividend 1 – SEK 1.34March 15                  Last day to trade fund units including the right to receive dividendMarch 16                  Ex-dividend; the fund units are traded ex dividendMarch 17                  Record dayMarch 22                  Payment day Dividend 2 – SEK 1.34 May 3

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

· The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percent[1] · The medication-assisted treatment (MAT) of opioid use disorder (OUD) requires a combination of drug and therapy treatment, where access and quality of counselling and psychosocial support are one of the main barriers to successful treatment · modia™ can help those with OUD by providing access to an evidence-based digital therapy rooted in cognitive behavioral techniques Uppsala, Sweden – February 10,

There are no items matching the current filter
There are no more items matching the current filter
Back to top